It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Zai Lab Limited (ZLAB) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.35, or 0.96%, to $36.99. The Zai Lab Limited has recorded 17,785 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Zai Lab Limited is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $36.64 and fluctuated between $37.81 as its day high and $35.61 as its day low. The current market capitalization of Zai Lab Limited is $3.60B. A total of 0.55 million shares were traded on the day, compared to an average of 713.84K shares.
In the most recent transaction, Edmondson Frazor Titus III sold 7,965 shares of ZLAB for 40.55 per share on Mar 06. After the transaction, the Chief Legal Officer now owns 19,400 company shares. In a previous transaction on Mar 03, Reinhart Harald sold 11,480 shares at 40.00 per share. ZLAB shares that insider owns now total 18,958.
Among the insiders who sold shares, Lis William disposed of 5,434 shares on Mar 03 at a per-share price of $38.31. This resulted in the Director holding 23,330 shares of ZLAB after the transaction. In another insider transaction, WIRTH PETER sold 4,000 shares at $35.33 per share on Dec 08. Company shares held by the Director now total 0.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for ZLAB in the last 3 months, the mean price target is $73.04 with high estimates of $138.00 and low estimates of $25.00. In terms of 52-week highs and lows, ZLAB has a high of $53.95 and a low of $20.98.
As of this writing, ZLAB has an earnings estimate of -$1.24 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.2 per share and a lower estimate of -$1.68. The company reported an EPS of -$0.9 in the last quarter, which was 25.00% higher than expectations of -$1.2.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 14 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ZLAB is Hold with a score of 5.00. A total of 12 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 1 thought it should be Sold.